SNX29

Across TCGA pan-cancer cohorts, SNX29 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SNX29 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SNX29 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNX29 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

CESC, ESCA, and MESO are the cancer types where SNX29 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
ESCA	DFS	Median	All	0.111	0.536	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	DFS	Median	All	0.927	0.625	.025	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
LUAD	OS	Median	All	0.480	0.790	.017	4	view →
SKCM	OS	Median	II,III,IV	1.000	0.278	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SNX29–CESC (OS)

Open the CESC breakdown →